Navigation Links
AtheroNova Releases 2011 Financial Results
Date:3/21/2012

IRVINE, Calif., March 21, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has released financial results for fiscal 2011.  As a development stage company, no revenues were recognized in the twelve months ended December 31, 2011.  Losses from operations were $2,560,235 for 2011 compared to $2,679,435 in 2010.  Net income was $4,263,286, or $0.17 per basic share ($0.15 diluted), in the year ended December 31, 2011 compared to a loss of $15,656,852, or ($0.70) per basic and diluted share, for the year ended December 31, 2010.

"This past year was a period of clear progress as we significantly enhanced our management team and scientific advisory board," said AtheroNova CEO Thomas W. Gardner. "The regression and prevention of atherosclerosis represents a multi-billion dollar market. This considerable market size and identifiable near term milestones positions us for a significant growth opportunity. We continue to remain on track with our development activities and 2012 will be a year of substantial evolution. We continue to advance the AHRO-001 product, as we recently announced the first shipment to our R&D partner, CardioNova; a clear milestone as we prepare for our upcoming human clinical trials. As CardioNova commences toxicology studies conducted for Russian regulatory purposes, we expect our progress to accelerate in the coming months as we achieve additional development milestones."

As the company continues to make progress it is important that its stakeholders are aware of the upcoming key milestones and highlights.

Key Near-Term Milestones

  • Q2'12 - Publication of pre-clinical studies anticipated
  • Q2'12 - IND filing
  • Q3'12 - Initiating Phase I clinical study
  • Q3'12 - FDA meeting pre Phase II
  • Q4'12 - Initiating Phase II Clinical study


  • '/>"/>
    SOURCE AtheroNova Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
    2. AtheroNova Announces a New Board Member
    3. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
    4. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
    5. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
    6. eCareSoft Releases eCS Cirrus™
    7. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
    8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
    9. Ion Torrent Gets Better Faster With 4th Qtr New Product Releases
    10. ICGC Releases New Genomic Data on Cancer Ahead of Schedule
    11. ACTE Releases Paper on How Career, Technical Student Organizations Expand Career Readiness for Students
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
    (Date:5/21/2015)... Bridgewater, NJ (PRWEB) May 21, 2015 ... and a method for diagnostic or therapeutic imaging within ... the apparatus uses an endoscope having a low cost, ... original USPTO filing date was October 18, 2013 and ... The technology enables the physician to customize the ...
    (Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
    (Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
    Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
    ... announced today that is has named Scott Canute, a former ... of Directors.   Over the course of his ... Eli Lilly,s global manufacturing operations.  Most recently, he spent more ... Operations for Genzyme, where he led a major turnaround effort. ...
    ... 12, 2011 - Two pivotal trials ... ulcerative colitis and Crohn,s disease - Shield ... the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals ... announced that the first patients have been treated in ...
    ... the search for new computing technologies, the University ... prestigious grants for cutting-edge nanoelectronics research that were ... Research Initiative (SRC-NRI) and the National Science Foundation. ... proposals each to the program," says Peter Kilpatrick, ...
    Cached Biology Technology:Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3Notre Dame researchers awarded millions to develop radically new computers 2
    (Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
    (Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
    (Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
    Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
    ... DALLAS Sept. 1, 2009 A process that ... differently than had been thought, opening the door to potential ... in the Aug. 7 issue of the journal Cell. ... only a certain number of times, via a countdown mechanism ...
    ... fail to respond to promising new medication. Researchers in ... for the development of this resistance. A "death receptor" ... chances of success are for chemotherapy. At the same ... tumor therapy. Dr. Wolf Mller, senior consultant in ...
    ... how fat causes hypertension have been identified by researchers who ... people and maybe some thin ones too are ... for them. Medical College of Georgia researchers have ... at risk for hypertension by interfering with an endogenous mechanism ...
    Cached Biology News:UT Southwestern researchers examine mechanisms that help cancer cells proliferate 2Why don't brain tumors respond to medication? 2New information about how fat increases blood pressure could help identify those at risk 2New information about how fat increases blood pressure could help identify those at risk 3
    ... 96 Well BAC Prep; Ideal ... from 1.5ml 2xYT cultures; Provides ... fluorescent sequencing for small to ... strategy which minimizes shearing and ...
    ... Well BAC Prep; Ideal for ... 1.5ml 2xYT cultures; Provides high-quality ... sequencing for small to large ... which minimizes shearing and improves ...
    Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
    Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
    Biology Products: